OncoOptima provides the OncoChoice® functional cancer drug activity testing service, which screens a patient’s fresh tumor biopsy ex vivo against a broad panel of approved and investigational drugs. By delivering quantitative viability and biomarker data along with ranked therapeutic recommendations and confidence scores, the platform gives oncologists actionable, patient‑specific insights to guide treatment selection for solid tumors.
Funding
Funding not disclosed
Founders
Product
Problem
Oncologists often lack reliable, patient-specific data on how a tumor will respond to individual cancer therapies, leading to trial-and-error prescribing and suboptimal treatment outcomes.
Solution
OncoOptima offers the OncoChoice® functional cancer drug activity testing service, which evaluates a patient’s tumor cells ex vivo against a panel of approved and investigational drugs. By measuring cellular viability and molecular response markers, the platform generates a ranked list of therapies most likely to be effective for that specific tumor. Results are delivered in a concise report that integrates with the clinician’s workflow, supporting more informed treatment selection and the potential to avoid ineffective or toxic regimens.
Target Audience
Primary users are oncologists and precision oncology teams seeking actionable, patient-specific drug response data for solid tumor patients.
Features
- Ex vivo drug screening of fresh tumor biopsies using a standardized assay platform
- Broad drug panel covering standard-of-care agents and targeted therapies
- Quantitative viability readouts and biomarker analysis to assess drug activity
- Ranked therapeutic recommendations with confidence scores
- Clinician-friendly report format compatible with electronic health record integration